Methods for treating myocardial infarction comprising administering an IL-6 inhibitor

Patent Citations (155)

Non-Patent Literature (305)

• Kobara et al (2010. Cardiovascular Research. 87; pp. 424-430).Examiner
• Matsushita et al, 2005. Laboratory Investigation. 85: 1210-1223.Examiner
• Wells (1990) Biochemistry 29(37): 8509-8517.Examiner
• Ngo et al (1994) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 433-440 and 492-495 only.Examiner
• Bork (2000) Genome Research 10:398.Examiner
• Skolnick et al (2000) Trends in Biotech. 18(1): 34.Examiner
• Doerks et al (1998) Trends in Genetics 14(6): 248.Examiner
• Brenner (1999) Trends in Genetics 15(4): 132.Examiner
• Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001.Examiner
• Vidal et al. 2005. European Journal of Cancer. 41: 2812-2818.Examiner
• Pirollo et al, 2008. Cancer Res. 68(5): 1247-1250.Examiner
• Wilansky (1991. Texas Heart Institute Journal. 18: 237-42).Examiner
• Guice et al., “Anti-tumor necrosis factor antibody augments edema formation in caerulein-induced acute pancreatitis,” J. Surg. Res., 51(6):495-9 (1991).Applicant
• Hocking et al., “Mechanisms of pulmonary edema induced by tumor necrosis factor-alpha,” Circ. Res., 67(1):68-77 (1990).Applicant
• Knulst et al., “Cytokine detection and modulation in acute graft vs. host disease in mice,” Mediators Inflamm., 3(1):33-40 (1994).Applicant
• Mukaida et al., rinsho kensa, 35(5):447-452 (1991).Applicant
• Murata et al., The Saishin-nigaku, 47(11):49-56 (1992).Applicant
• Ulich et al., “Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation,” Am. J. Pathol., 138(5):1097-1101 (1991).Applicant
• Borsellino et al., “Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity,” Cancer, 85:134-44 (1999).Applicant
• Culig et al., “Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth,” Mol. Cell. Endocrinol., 197:231-238 (2002).Applicant
• Davies et al, “The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo,” Int. J. Cancer, 106:348-354 (2003).Applicant
• Eder et al., “Targeting the androgen receptor in hormone-refractory prostate cancer—new concepts,” Future Oncol., 1:93-101 (2005).Applicant
• Lee et al., “Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway,” Prostate, 60:178-186 (2004).Applicant
• Paule, “Reappraisal of the concept of hormone therapy in metastatic prostate cancer and implications for treatment,” Eur. Urol., 47:729-735 (2005).Applicant
• Trikha et al., “Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence,” Clin. Cancer Res., 9:4653-65 (2003).Applicant
• Xing et al., “The effect of interleukin-6 on the proliferation of prostate cancer cells in vitro and the modulation of this procedure,” J. Tongji Med. Univ., 21:225-227 (2001).Applicant
• European Search Report for App. Ser. No. 06 83 3196, dated Aug. 27, 2009, 5 pages.Applicant
• Akira et al., “Interleukin-6 in biology and medicine,” Adv. Immunol., 54:1-78 (1993).Applicant
• Ding et al., “The change of plasma interleukin-6 level and cardiac protective effect of monoclonal antibody to IL-6 during myocardial infarction reperfusion,” Chin. J. Cardiol., 27:29-32 (1999) (with English Abstract).Applicant
• Finkel et al., “Negative inotropic effects of cytokines on the heart mediated by nitric oxide,” Science 257:387-389 (1992).Applicant
• Fuchs et al., “Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction,” FASEB J., 17: 2118-20 (2003).Applicant
• Gwechenberger et al., “Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions,” Circulation 99:546-551 (1999).Applicant
• Hirano et al., “Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin,” Nature, 324:73-76 (1986).Applicant
• Hirata et al., “Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies,” J. Immunol., 143:2900-06 (1989).Applicant
• Hirota et al., “Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice,” Proc. Natl. Acad. Sci. USA, 92:4862-66 (1995).Applicant
• Huang et al., “A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells,” Hybridoma, 12:621-630 (1993).Applicant
• Lotz et al., “B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes,” J. Exp. Med., 167:1253-58 (1988).Applicant
• Negoro et al., “Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction,” Cardiovas. Res., 47:797-805 (2000).Applicant
• Novick et al., “Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding,” Hybridoma, 10:137-146 (1991).Applicant
• Ono et al., “Cytokine gene expression after myocardial infarction in rat hearts,” Circulation, 98:149-156 (1998).Applicant
• Taga et al, “Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130,” Cell, 58:573-581 (1989).Applicant
• Taga et al., “Receptors for B cell stimulatory factor 2,” J. Exp. Med., 166:967-981 (1987).Applicant
• Yamasaki et al., “Cloning and expression of the human interleukin-6 (BSF-2/IFNβ 2) receptor,” Science, 241:825-828 (1988).Applicant
• Yamauchi-Takihara et al., “Hypoxic stress induces cardiac myocyte-derived interleukin-6,” Circulation, 91:1520-24 (1995).Applicant
• Yue et al., “Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure,” Am. J. Physiol., 275:H250-H258 (1998).Applicant
• Furukawa et al., “Cytokine gene expression during the development of graft coronary artery disease in mice,” Jpn.Cir. J., 63:775-782 (1999).Applicant
• Hornick et al., “Chronic rejection in the heart,” Methods Mol. Biol., 333:131-144 (2006).Applicant
• Izawa et al., “Critical Role of Interleukin-6 and its Crosstalk with AT1R Signaling in Acute Rejection of Murine Cardiac Allografts,” Circulation Journal, 71 (Suppl. 1):392 (#PE-269), Annual Scientific Meeting of the Japanese Circulation Society, Kobe, Japan (2007).Applicant
• Izawa et al., “Interleukin-6 Blockade Attenuates the Development of Both Acute and Chronic Rejection of Murine Cardiac Allografts: A Potential Crosstalk between Interleukin-6 and Signaling through Angiotensin II Type 1 Receptor,” American Journal of Transplantation, 7 (Suppl. 11):426 (#1084), American Transplant Congress, San Francisco, CA (2007).Applicant
• Kurek et al., “The Role of Leukemia Inhibitory Factor in Skeletal Muscle Regeneration,” Muscle Nerve, 20:815-822 (1997).Applicant
• Ramzy et al., “Cardiac allograft vasculopathy: a review,” Can. J. Surg., 48:319-327 (2005).Applicant
• Valantine, “Cardiac allograft vasculopathy after heart transplantation: risk factors and management,” J. Heart Lung Transplant., 23(5 Suppl.):S187-S193 (2004).Applicant
• Webber et al., “Heart and lung transplantation in children,” Lancet, 368:53-69 (2006).Applicant
• Wong et al., “Progress in heart transplantation,” Cardiovasc. Pathol., 14:176-180 (2005).Applicant
• International Search Report for App. Ser. No. PCT/JP2008/050842, mailed on Feb. 19, 2008, 2 pages.Applicant
• Bellomo, “The Cytokine Network in the Critically Ill,” Anaesth. Intensive Care, 20(3):288-302 (1992).Applicant
• U.S. Appl. No. 12/085,065, filed Jun. 1, 2009, Okada et al.Applicant
• U.S. Appl. No. 12/094,644, filed Feb. 27, 2009, Nakashima et al.Applicant
• U.S. Appl. No. 12/161,733, filed Jul. 22, 2008, Ishida.Applicant
• U.S. Appl. No. 12/296,193, filed Apr. 15, 2009, Nishimoto et al.Applicant
• Alvarez et al., “Tumor necrosis factor-α exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells,” Biochim. Biophys. Acta, 1542:66-72 (2002).Applicant
• Barton-Davis et al., “Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function,” Proc. Natl. Acad. Sci. USA, 95:15603-07 (1998).Applicant
• Benda et al., “Interleukin-6 in islet xenograft rejection,” Transplant Int., 14:63-71 (2001).Applicant
• Bogdanovich et al., “Functional improvement of dystrophic muscle by myostatin blockade,” Nature, 420:418-421 (2002).Applicant
• Campbell et al., “Essential role for interferon-γ and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice,” J. Clin. Invest., 87:739-742 (1991).Applicant
• Campbell et al., “Evidence for IL-6 production by and effects on the pancreatic β-cell,” J. Immunol., 143:1188-91 (1989).Applicant
• Choi et al., “IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo,” Transpl. Immunol., 13:43-53 (2004).Applicant
• Dangott et al., “Dietary creatine monohydrate supplementation increases satellite cell mitotic activity during compensatory hypertrophy,” Int. J. Sports Med., 21:13-16 (2000).Applicant
• Darr and Schultz, “Hindlimb suspension suppresses muscle growth and satellite cell proliferation,” J. Appl. Physiol., 67:1827-34 (1989).Applicant
• Fredj et al., “Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation,” J. Cell. Physiol., 204:428-436 (2005).Applicant
• Garry et al., “Myogenic stem cell function is impaired in mice lacking the forkhead/winged helix protein MNF,” Proc. Natl. Acad. Sci. USA, 97:5416-21 (2000).Applicant
• Garry et al., “Persistent expression of MNF identifies myogenic stem cells in postnatal muscles,” Dev. Biol., 188:280-294 (1997).Applicant
• Grossniklaus and Green, “Choroidal neovascularization,” Am. J. Ophthalmol., 137:496-503 (2004).Applicant
• Horinaga et al., “Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer,” Urology, 66:671-675 (2005).Applicant
• Ito et al., Journal of Japan Surgical Society 107 (special extra issue 2):387, PS-014-5 (2006) (English translation included).Applicant
• Itoh et al., “Anti-IL-6 receptor antibody down-regulates pro-inflammation cytokine production of Gr-1*CD11b* cells and prevents early loss of islet grafts in the liver of mice in association with engraftments,” Transplantation 82(Supp. 3), World Transplant Congress 2006, Abstract No. 2838.Applicant
• Jejurikar et al., “Skeletal muscle denervation increases satellite cell susceptibility to apoptosis,” Plast. Reconstr. Surg., 110:160-168 (2002).Applicant
• Kami et al., “Gene expression of receptors for IL-6, LIF, and CNTF in regenerating skeletal muscles,” J. Histochem. Cytochem., 48:1203-13 (2000).Applicant
• Kurek et al., “Up-regulation of leukaemia inhibitory factor and interleukin-6 in transected sciatic nerve and muscle following denervation,” Neuromuscul. Disord., 6:105-114 (1996).Applicant
• Kuroda et al., “Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer,” Clin. Cancer Res., 11:5590-94 (2005).Applicant
• Mauro, “Satellite cell of skeletal muscle fibers,” J. Biophys. Biochem. Cytol., 9:493-495 (1961).Applicant
• McCormick and Schultz, “Role of satellite cells in altering myosin expression during avian skeletal muscle hypertrophy,” Dev. Dyn., 199:52-63 (1994).Applicant
• Moss and Leblond, “Satellite cells as the source of nuclei in muscles of growing rats,” Anat. Rec., 170:421-435 (1971).Applicant
• Mozdziak et al., “Hindlimb suspension reduces muscle regeneration,” Eur. J. Appl. Physiol., 78:136-140 (1998).Applicant
• Mozdziak et al., “Muscle regeneration during hindlimb unloading results in a reduction in muscle size after reloading,” J. Appl. Physiol., 91:183-190 (2001).Applicant
• Mozdziak et al., “Quantitation of satellite cell proliferation in vivo using image analysis,” Biotech. Histochem., 69:249-252 (1994).Applicant
• Mozdziak et al., “Unloading of juvenile muscle results in a reduced muscle size 9 wk after reloading,” J. Appl. Physiol., 88:158-164 (2000).Applicant
• Murphy, “The effect of mechanical stretch on proliferation and differentiation of C2C12 cells,” FASEB J., 18:A743 (Abstract #476.6) (2004).Applicant
• Nagai et al., Ensho-Saisei (Inflammation and Regeneration), Jul. 2006; 26(4):367 (#90) (English translation included).Applicant
• Nakashima et al., “Serum interleukin 6 as a prognostic factor in patients with prostate cancer,” Clin. Cancer Res., 6:2702-06 (2000).Applicant
• Nishimoto and Kishimoto, “Inhibition of IL-6 for the treatment of inflammatory diseases,” Curr. Opin. Pharmacol., 4:386-391 (2004).Applicant
• Okamoto et al., “Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro,” Cancer Res., 57:141-146 (1997).Applicant
• Okazaki et al., “Characterization of anti-mouse interleukin-6 receptor antibody,” Immunol. Lett., 84:231-240 (2002).Applicant
• Pauleikhoff, “Neovascular age-related macular degeneration,” Retina, 25:1065-84 (2005).Applicant
• Schultz et al., “Response of satellite cells to focal skeletal muscle injury,” Muscle Nerve, 8:217-222 (1985).Applicant
• Schultz, “Acute effects of hindlimb unweighting on satellite cells of growing skeletal muscle,” J. Appl. Physiol., 76:266-270 (1994).Applicant
• Schultz, “Satellite cell proliferative compartments in growing skeletal muscles,” Dev. Biol., 175:84-94 (1996).Applicant
• Seddon et al., “Progression of age-related macular degeneration,” Arch. Ophthalmol., 123:774-782 (2005).Applicant
• Shimazaki et al., “Hito Kotsuzuishu Model to Ko hito IL-6 Juyotai Kotai no Ko Shuyo Koka,” Rinsho Ketsueki, 38:281-284 (1997) (English translation provided).Applicant
• Smith et al., “Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice,” Prostate, 48:47-53 (2001).Applicant
• Snow, “Myogenic cell formation in regenerating rat skeletal muscle injured by mincing,” Anat. Rec., 188:181-199 (1977).Applicant
• Snow, “Satellite cell response in rat soleus muscle undergoing hypertrophy due to surgical ablation of synergists,” Anat. Rec., 227:437-446 (1990).Applicant
• Tsujinaka et al., “Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice,” J. Clin. Invest., 97:244-249 (1996).Applicant
• Wang et al., “Mechanical load-dependent regulation of satellite cell and fiber size in rat soleus muscle,” Am. J. Physiol. Cell. Physiol., 290:C981-C989 (2006).Applicant
• Warren et al., “Physiological role of tumor necrosis factor I in traumatic muscle injury,” FASEB J., 16:1630-32 (2002).Applicant
• Zaki et al., “CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice,” Int. J. Cancer, 111:592-595 (2004).Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/320441, dated Apr. 16, 2008, 5 pages.Applicant
• Japanese Patent Office, International Search Report for App. Ser. No. PCT/JP2006/320441, mailed Dec. 19, 2006, 2 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/320905, dated Apr. 22, 2008, 8 pages.Applicant
• Japanese Patent Office, International Search Report for App. Ser. No. PCT/JP2006/320905, mailed Jan. 16, 2007, 2 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/322726, dated May 20, 2008, 9 pages.Applicant
• Japanese Patent Office, International Search Report for App. Ser. No. PCT/JP2006/322726, mailed Jan. 19, 2007, 5 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/323392, dated May 27, 2008, 9 pages.Applicant
• Japanese Patent Office, International Search Report for App. Ser. No. PCT/JP2006/323392, mailed Jan. 9, 2007, 4 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/051226, dated Jul. 29, 2008, 6 pages.Applicant
• Japanese Patent Office, International Search Report for App. Ser. No. PCT/JP2007/051226, mailed May 1, 2007, 2 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/057745, dated Nov. 17, 2008, 6 pages.Applicant
• Japanese Patent Office, International Search Report for App. Ser. No. PCT/JP2007/057745, mailed Jul. 10, 2007, 2 pages.Applicant
• Shimizu et al., “Cancer anti-angiogenic therapy,” Biol. Pharm. Bull., 27(5):599-605 (2004).Applicant
• Stan et al., “In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor,” J. Neurosurg., 82(6):1044-52 (1995).Applicant
• Tobe et al., “Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model,” Am. J. Pathol., 153(5):1641-6 (1998).Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/090,061, dated Aug. 27, 2010, 5 pages.Applicant
• Ford et al., “Evidence that Production of Interleukin 6 within the Rejecting Allograft Coincides with Cytotoxic T Lymphocyte Development,” Transplantation, 51(3):656-661 (1991).Applicant
• Luo et al., “A Proteasome Inhibitor Effectively Prevents Mouse Heart Allograft Rejection,” Transplantation, 72(2):196-202 (2001).Applicant
• European Search Report for App. Ser. No. EP 06 83 2657, dated Nov. 25, 2009, 5 pages.Applicant
• Biswas et al., “Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection,” Exp. Eye Res., 82(1):46-54 (2006).Applicant
• Giugliano et al., “Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts,” Br. J. Plast. Surg., 56(8):804-809 (2003).Applicant
• Hoffman et al., “Inhibitory effects of verapamil isomers on the proliferation of choroidal endothelial cells,” Graefe's Arch. Clin. Exp. Ophthalmol., 244(3)376-381 (2006).Applicant
• Park et al., “Interleukin-6 protects MIN6 beta cells from cytokine-induced apoptosis,” Ann. N.Y. Acad. Sci., 1005:242-249 (2003).Applicant
• European Search Report for App. Ser. No. EP 06 81 1729, dated Nov. 17, 2009, 5 pages.Applicant
• European Search Report for App. Ser. No. 07 70 7458, dated Nov. 30, 2009, 5 pages.Applicant
• Quentmeier et al., “Role of IL-6, IL-2, and IL-4 in the in Vitro Induction of Cytotoxic T Cells,” J. Immunol., 149(10):3316-3320 (1992).Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/085,065, dated Apr. 30, 2010, 8 pages.Applicant
• Jeron et al., “Systemic Immunosuppression Fails to Suppress Cardiac Cytokine induction in Pressure Overload Hypertrophy in Rats,” Immunobiology, 205(1):51-60 (2002).Applicant
• Kobara et al., “Inhibition of interleukin-6 signaling attenuates left ventricular remodeling after myocardial infarction in mice,” Journal of the American Heart Association, 112(17):851 (2005).Applicant
• Kurdi et al., “Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats,” Molecular and Cellular Biochemistry, 269(1):95-101 (2005).Applicant
• Okamoto et al., “Inhibition of Interleukin-6 Signaling Attenuates Left Ventricular Remodeling After Experimental Myocardial Infarction,” Journal of Cardiac Failure, 11(9): P066 (2005).Applicant
• European Search Report for App. Ser. No. EP 06 81 2073, dated Nov. 20, 2009, 6 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/085,065, dated Nov. 26, 2010, 12 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/161,733, dated Jan. 13, 2011, 7 pages.Applicant
• Klarquist Sparkman, LLP response to Restriction Requirement dated Oct. 5, 2010 in U.S. Appl. No. 12/296,193, filed Nov. 2, 2010, 2 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/296,193, dated Dec. 20, 2010, 12 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/094,644, dated Feb. 2, 2011, 5 pages.Applicant
• Fish & Richardson P.C., Response to Requirement dated Aug. 27, 2010 in U.S. Appl. No. 12/090,061, filed Feb. 24, 2011, 1 page.Applicant
• Fisniku et al., “Protective effects of PG490-88 on chronic allograft rejection by changing intragraft gene expression profiles,” Transplant Proc., 37:1962-1964 (2005).Applicant
• Kallen et al., “New developments in IL-6 dependent biology and therapy: where do we stand and what are the options?,” Expert Opin. Investig. Drugs, 8(9):1327-49 (1999).Applicant
• Matsuda et al., “Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies,” Eur. J. Immunol., 18:951-956 (1988).Applicant
• Shimizu et al., “KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts,” Circulation, 111:222-229 (2005).Applicant
• Tamura et al., “Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6,” Proc. Natl. Acad. Sci. U.S.A., 90:11924-11928 (1993).Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Apr. 30, 2010 in U.S. Appl. No. 12/085,065, filed Oct. 22, 2010, 2 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/296,193, dated Oct. 5, 2010, 6 pages.Applicant
• Choy et al., “Inhibiting interleukin-6 in rheumatoid arthritis,” Curr. Rheumatol. Rep., 10(5):413-7 (2008).Applicant
• Ewert et al., “Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering,” Methods, 34:184-199 (2004).Applicant
• Guerne et al., “Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis,” J. Clin. Invest., 83(2):585-92 (1989).Applicant
• Hanes et al., “Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display,” Nat. Biotechnol., 18(12):1287-92 (2000).Applicant
• Hirano et al., “Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis,” Eur. J. Immunol., 18(11):1797-801 (1988).Applicant
• Houssiau et al., “Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides,” Arthritis Rheum., 31(6):784-8 (1988).Applicant
• Kishimoto, “The biology of interleukin-6,” Blood, 74(1):1-10 (1989).Applicant
• Kotake et al., “Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation,” J. Bone Miner Res., 11(1):88-95 (1996).Applicant
• Madhok et al., “Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity,” Ann. Rheum. Dis., 52(3):232-4 (1993).Applicant
• Nishimoto et al., “Interleukin 6: from bench to bedside,” Nat. Clin. Pract. Rheumatol., 2(11):619-26 (2006).Applicant
• Sack et al., “Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis,” Rheumatol. Int., 13(2):45-51 (1993).Applicant
• USPTO Notice of Allowance in U.S. Appl. No. 12/090,061, dated Aug. 27, 2012, 9 pages.Applicant
• Akira et al., “The evidence for interleukin-6 as an autocrine growth factor in malignancy,” Semin Cancer Biol., 3:17-26 (1992).Applicant
• Armstrong et al., “Melanoma-derived interleukin 6 inhibits in vivo melanoma growth,” J Invest Dermatol., 102:278-284 (1994).Applicant
• Becker, Y., “Molecular immunological approaches to biotherapy of human cancers—a review, hypothesis and implications,” Anticancer Res., 26:1113-1134 (2006).Applicant
• Cabillic et al., “Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk,” Clin Exp Immunol., 146:518-523 (2006).Applicant
• Duluc et al., “Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells,” Blood, 110:4319-4330 (2007).Applicant
• Porgador et al., “Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells,” Cancer Res., 52:3679-3686 (1992).Applicant
• Sebba, A., “Tocilizumab: the first interleukin-6-receptor inhibitor,” Am J Health Syst Pharm., 65:1413-1418 (2008).Applicant
• Suzuki et al., “Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity,” Clin Cancer Res., 11:6713-6721 (2005).Applicant
• Tanaka et al., “The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector,” Cancer Res., 57:1335-1343 (1997).Applicant
• Vincent et al., “5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity,” Cancer Res., 70:3052-3061 (2010).Applicant
• Zangari et al., “Immunomodulatory drugs in multiple myeloma,” Expert Opin Investig Drugs, 14:1411-1418 (2005).Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/085,065, dated Jan. 11, 2013, 14 pages.Applicant
• Hanahan et al., “Hallmarks of cancer: the next generation,” Cell, 144:646-674 (2011).Applicant
• Tsuchiya, M., “Therapeutic Antibody,” Credit Suisse Seminar at Fuji-Gotemba Research Laboratories, p. 21, Shizuoka, Japan (2006) (with English translation).Applicant
• USPTO Notice of Allowance in U.S. Appl. No. 12/085,065, dated Sep. 24, 2013, 10 pages.Applicant
• Sterne, Kessler, Goldstein & Fox P.L.L.C, Reply to Office Action dated Mar. 15, 2013 in U.S. Appl. No. 12/524,041, filed Sep. 13, 2013, 6 pages.Applicant
• U.S. Appl. No. 13/700,355, filed Nov. 27, 2012, Nishimura.Applicant
• Hirai et al., “Perineural invasion in pancreatic cancer,” Pancreas, 24(1):15-25 (2002).Applicant
• Martignoni et al., “Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia,” Clin. Cancer Res., 11(16):5802-5808 (2005).Applicant
• Miyamoto et al., “Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells,” Anticancer Res., 21:2449-2456 (2001).Applicant
• Okada et al., “Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF),” Int. J Cancer, 81:67-73 (1999).Applicant
• Takahashi et al., “Antiproteases in preventing the invasive potential of pancreatic cancer cells,” JOP, 8(4 Suppl.):501-508 (2007).Applicant
• Sterne, Kessler, Goldstein & Fox P.L.L.C, Response to Restriction Requirement dated Jun. 1, 2012 in U.S. Appl. No. 12/996,162, filed Jun. 28, 2012, 4 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/996,162, dated Sep. 12, 2012, 8 pages.Applicant
• Berger et al., “Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis,” Proc Natl Acad Sci USA, 107:2995-3000 (2010).Applicant
• Kim et al., “Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis,” Nature, 457:102-106 (2009).Applicant
• Shewach et al., “Gemcitabine and radiosensitization in human tumor cells,” Invest New Drugs, 14:257-263 (1996).Applicant
• USPTO Final Office Action in U.S. Appl. No. 12/524,041, dated Oct. 15, 2012, 6 pages.Applicant
• Sterne, Kessler, Goldstein & Fox P.L.L.C, Amendment and Reply to Office Action dated Oct. 15, 2012 in U.S. Appl. No. 12/524,041, filed Jan. 15, 2013, 7 pages.Applicant
• Huang et al., “Inhibitory effect of AG490 on invasion and metastasis of human pancreatic cancer cells in vitro,” Chin. J. Oncol., 28:890-892, Wanfang Data Co., Ltd., Beijing, China (2006) (in Chinese, with English abstract).Applicant
• Huang et al., “Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro,” Cancer Sci., 97:1417-1423, Japanese Cancer Association, Tokyo, Japan (2006).Applicant
• Okada et al., “Elevated serum interleukin-6 levels in patients with pancreatic cancer,” Japan J. Clin. Oncol., 28:12-15, Foundation of Clinical Oncology, Tokyo, Japan (1998).Applicant
• USPTO Notice of Allowance in U.S. Appl. No. 12/090,061, dated Mar. 22, 2013, 9 pages.Applicant
• USPTO Office Action in U.S. Appl. No. 12/524,041, dated Mar. 15, 2013, 5 pages.Applicant
• Sterne, Kessler, Goldstein & Fox P.L.L.C, Amendment and Reply to Office Action dated Sep. 12, 2012 in U.S. Appl. No. 12/996,162, filed Mar. 12, 2013, 14 pages.Applicant
• USPTO Final Office Action in U.S. Appl. No. 12/996,162, dated Mar. 20, 2013, 11 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 13/387,292, dated Jan. 31, 2013, 8 pages.Applicant
• Sterne, Kessler, Goldstein & Fox P.L.L.C, Response to Restriction Requirement dated Jan. 31, 2013 in U.S. Appl. No. 13/387,292, filed Mar. 1, 2013, 2 pages.Applicant
• USPTO Office Action in U.S. Appl. No. 13/387,292, dated Mar. 26, 2013, 7 pages.Applicant
• Hatzi et al., “N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth,” Oncogene, 21(22):3552-61 (2002).Applicant
• Konopatskaya et al., Mol Vis., Monday, May 1, 2006, 11:15 AM—1:00 PM Hall B/C Poster Session Program Number/Board # Range: 1749-1764/B836-B851, 244. Antiangiogenesis: Basic Mechanisms.Applicant
• Ogata et al., “Anti-IL-6 receptor antibody does not ameliorate radiation pneumonia in mice,” Exp. Ther. Med., 4:273-276 (2012).Applicant
• Ogata et al., “Early administration of IL-6RA does not prevent radiation-induced lung injury in mice,” Radiat. Oncol., 5:26 (2010).Applicant
• Mukaida et al., “Cytokines and immune network,” Rinshou Kensa, 35(5):447-452 (1991) (with English translation).Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Jan. 11, 2013 in U.S. Appl. No. 12/085,065, filed Jul. 11, 2013, 18 pages.Applicant
• Guillén et al., “Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6,” Am. J. Physiol., 269(2 Pt 2):R229-35 (1995).Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/524,041, dated Aug. 29, 2011, 6 pages.Applicant
• Sterne, Kessler, Goldstein & Fox P.L.L.C., Response to Restriction Requirement dated Aug. 29, 2011 in U.S. Appl. No. 12/524,041, filed Oct. 28, 2011, 2 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/524,041, dated Dec. 21, 2011, 7 pages.Applicant
• Beck et al., “Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody,” N. Engl. J. Med., 330:602-605 (1994).Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Apr. 11, 2012 in U.S. Appl. No. 12/085,065, filed Oct. 9, 2012, 10 pages.Applicant
• Fish & Richardson P.C., Amendment and Reply to Office Action dated Apr. 9, 2012 in U.S. Appl. No. 12/161,733, filed Oct. 9, 2012, 13 pages.Applicant
• Sterne, Kessler, Goldstein & Fox P.L.L.C, Amendment and Reply to Office Action dated Mar. 26, 2013 in U.S. Appl. No. 13/387,292, filed Sep. 25, 2013, 18 pages.Applicant
• Yoshio-Hoshino et al., “Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor,” Cancer Res., 67:871-875 (2007).Applicant
• Paul, W.E. (Ed.), Fundamental Immunology, 3rd ed., New York: Raven Press, 1993, p. 1124-1125.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/090,061, dated May 3, 2011, 11 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Nov. 26, 2011 in U.S. Appl. No. 12/085,065, filed May 25, 2011, 9 pages.Applicant
• Campo et al., “Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma,” Cytokine, 31(5):368-74 (2005).Applicant
• Campochiaro, “Retinal and choroidal neovascularization,” J. Cell Physiol., 184:301-310 (2000).Applicant
• Chuntharapai et al., “Generation of monoclonal antibodies to chemokine receptors,” Methods Enzymol., 288:15-27 (1997).Applicant
• Fujita et al., “Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways,” Int. J. Cancer, 68(5):637-643 (1996).Applicant
• Greenberg et al., “Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia,” Cancer Res., 52(15):4113-4116 (1992).Applicant
• Idezawa et al., “Interleukin-6 Functions as an Autocrine Invasion Factor of Human Pancreatic Cancer Cells,” Yamanashi Med. J., 19(2):53-67 (2004).Applicant
• Idezawa et al., “Interleukin-6 Functions as an Autocrine Invasion Factor of Human Pancreatic Cancer Cells,” Yamanashi Med. J., 20(2):xxxvi (2005).Applicant
• Kamohara et al., “IL-6 no Suigan Saibo no Zoshoku-Ten'i Oyobosu Eikyo to Kanshitsu Saibo ni yoru Hatsugen Seigyo Kiko,” Japanese Journal of Gastroenterological Surgery, 39(7):1356 (Abstract 2529) (2006).Applicant
• Nishimoto et al., “Anti-interleukin 6 receptor antibody treatment in rheumatic disease,” Ann Rheum. Dis., 59 Suppl 1:i21-27 (2000).Applicant
• Ono et al., “The effect of IL-6 on the des-gamma-carboxy prothrombin synthesis in human hepatoma cells,” Gastroenterologia Japonica, 27(6):745-50 (1992).Applicant
• Ohtsuka et al., “Relation of circulating interleukin-6 to left ventricular remodeling in patients with reperfused anterior myocardial infarction,” Clin. Cardiol., 27(7):417-420 (2004).Applicant
• Patel et al., “Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion,” J. Pharmacol. Exp. Ther., 312(3):1170-1178 (2005).Applicant
• Puhakka et al., “Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation,” J. Card. Fail., 9(4):325-332 (2003).Applicant
• Q&A de wakaru himan to tounyoubyou, 3(6):982-984 (2004) (with English translation).Applicant
• Sato et al., “Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth,” Cancer, 53:851-856 (1993).Applicant
• Skurkovich et al., “Anticytokine therapy—new approach to the treatment of autoimmune and cytokine-disturbance diseases,” Med. Hypotheses, 59(6):770-780 (2002) (in the Russian language. Relevant portions are in the English language).Applicant
• Strassmann et al., “Evidence for the involvement of interleukin 6 in experimental cancer cachexia,” J. Clin. Invest., 89(5):1681-1684 (1992).Applicant
• Tisdale, MJ., “Biology of cachexia,” J. Natl. Cancer Inst., 89(23):1763-73 (1997).Applicant
• Fish & Richardson P.C., Amendment in Reply to Office Action dated May 3, 2011 in U.S. Appl. No. 12/090,061, filed Nov. 1, 2011, 11 pages.Applicant
• USPTO Notice of Allowance in U.S. Appl. No. 12/085,065, dated Aug. 22, 2011, 8 pages.Applicant
• USPTO Notice of Allowance in U.S. Appl. No. 12/085,065, dated Jan. 11, 2012, 7 pagess.Applicant
• Fish & Richardson P.C., Response to Species Election Requirement dated Feb. 2, 2011 in U.S. Appl. No. 12/094,644, filed Jul. 25, 2011, 2 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/094,644, dated Sep. 26, 2011, 6 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Jan. 13, 2011 in U.S. Appl. No. 12/161,733, filed Jul. 7, 2011, 1 page.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/161,733, dated Aug. 16, 2011, 20 pages.Applicant
• Fish & Richardson P.C., Amendment and Reply to Office Action dated Aug. 16, 2011 in U.S. Appl. No. 12/161,733, filed Feb. 15, 2012, 13 pages.Applicant
• USPTO Final Office Action in U.S. Appl. No. 12/161,733, dated Apr. 9, 2012, 20 pages.Applicant
• Klarquist Sparkman, LLP, Amendment and Reply to Office Action dated Dec. 20, 2010 in U.S. Appl. No. 12/296,193, filed Jun. 20, 2011, 24 pages.Applicant
• USPTO Final Office Action in U.S. Appl. No. 12/296,193, dated Jul. 26, 2011, 20 pages.Applicant
• Klarquist Sparkman, LLP, Amendment and Reply to Office Action dated Jul. 26, 2011 in U.S. Appl. No. 12/296,193, filed Jan. 26, 2012, 10 pages.Applicant
• Klarquist Sparkman, LLP, Supplemental Amendment and Response in U.S. Appl. No. 12/296,193, filed Mar. 19, 2012, 6 page.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/524,041, dated Aug. 29, 2011, 6 pages.Applicant
• Sterne, Kessler, Goldstein & Fox P.L.L.C, Amendment and Reply to Office Action dated Aug. 29, 2011 in U.S. Appl. No. 12/524,041, filed Jun. 20, 2012, 7 pages.Applicant
• European Search Report for App. Ser. No. 07 741 181.7, mailed Dec. 23, 2009, 6 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2009/060314, mailed Aug. 11, 2009, 7 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2009/060314, mailed Jan. 11, 2011, 8 pages.Applicant
• European Search Report for App. Ser. No. 08 703 686.9, mailed Aug. 24, 2010, 12 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/090,061, dated Jan. 12, 2012, 8 pages.Applicant
• Fish & Richardson P.C., Amendment and Reply to Action dated Sep. 26, 2011 in U.S. Appl. No. 12/094,644, filed Mar. 21, 2012, 9 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/085,065, dated Apr. 11, 2012, 8 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/094,644, dated May 22, 2012, 10 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Office Action dated Jan. 12, 2012 in U.S. Appl. No. 12/090,061, filed Jun. 11, 2012, 12 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/996,162, dated Jun. 1, 2012, 8 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2010/062874, mailed Feb. 7, 2012, 9 pages.Applicant
• Chung et al., “Serum interleukin-6 levels reflect the disease status of colorectal cancer,” J Surg Oncol., 83:222-226 (2003).Applicant
• Jones et al., “Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass,” The FASEB Journal express article 10.1096/fj.03-1228fje, pp. 1-27. Published online Apr. 14, 2004.Applicant
• Michalaki et al., “Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer,” Br J Cancer, 90:2312-2316 (2004).Applicant
• Mitsunaga et al., “Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact,” Am J Surg Pathol., 31:1636-1644 (2007).Applicant
• Mitsunaga et al., “Nerve invasion distance is dependent on laminin gamma2 in tumors of pancreatic cancer,” Int J Cancer, 127:805-819 (2010).Applicant
• Zhang et al., “Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma,” Anticancer Res., 19:1427-1432 (1999).Applicant
• Nishimoto et al., “Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan,” Clin. Rev. Allergy Immunol., 28(3):221-30 (2005).Applicant
• Roitt et al., Immunology, M. Mir, p. 110 (2000) (with English translation).Applicant
• Yokota et al., “Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis,” Clin. Rev. Allergy Immunol., 28(3):231-8 (2005).Applicant
• Hirota et al., “Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress,” Cell 97(2):189-98 (1999).Applicant
• Ashizawa et al., “Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor,” Gastric Cancer, 8:124-131 (2005).Applicant
• Bond et al., “Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B,”FEBS Lett., 435:29-34 (1998).Applicant
• Gao et al., “Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas,” J. Clin. Invest., 117(12):3846-3856 (2007)\.Applicant
• Ghosh et al., “Missing pieces in the NF-kappaB puzzle,” Cell, 109:S81-S96 (2002).Applicant
• Greten et al., “IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer,” Cell, 118:285-296 (2004).Applicant
• Karin et al., “NF-kappaB at the crossroads of life and death,” Nat. Immunol., 3(3):221-227 (2002).Applicant
• Karin et al., “NF-kappaB in cancer: from innocent bystander to major culprit,” Nat. Rev. Cancer, 2:301-310 (2002).Applicant
• Maeda et al., “IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis,” Cell, 121:977-990 (2005).Applicant
• Maeda et al., “Ikappa B kinasebeta/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression,” Hepatology, 50:1851-1860 (2009).Applicant
• Matzaraki et al., “Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis,” Clin. Biochem., 40:336-342 (2007).Applicant
• Naugler et al., “Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production,” Science, 317:121-124 (2007).Applicant
• Pikarsky et al., “NF-kappaB functions as a tumour promoter in inflammation-associated cancer,” Nature, 431:461-466 (2004).Applicant
• Sansone et al., “IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland,” J. Clin. Invest., 117(12):3988-4002 (2007).Applicant
• Sarkar et al., “Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy,” Mini Rev. Med. Chem., 7:599-608 (2007).Applicant
• Steeg et al., “Tumor metastasis: mechanistic insights and clinical challenges,” Nat. Med., 12(8):895-904 (2006).Applicant
• Steeg, “Metastasis: a therapeutic target for cancer,” Nat. Clin. Pract. Oncol., 5(4):206-219 (2008).Applicant
• Studebaker et al., “Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner,” Cancer Res., 68(21):9087-9095 (2008).Applicant
• Takeda et al., “Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6,” Jpn. J. Cancer Res., 82:1299-1308 (1991).Applicant
• Yamakawa et al., “Astrocytes promote the proliferation of lung cancer cells in brain metastases via inflammatory cytokines, especially IL-6,” Neuroscience, 48(2/3):216, P-22 (poster presentation) (2009).Applicant
• International Search Report for App. Ser. No. PCT/JP2010/062874, mailed Aug. 31, 2010, 2 pages.Applicant
• Ohsugi et al., “Pharmacological and Clinical Profile of Humanized Anti-human IL-6 Receptor Antibody (Tocilizumab), a Therapeutic Drug for Castleman's Disease,” Nihon Yakurigaku Zasshi, 126(6):419-25 (Dec. 2005); 23 pages with an English language translation.Applicant
• Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. U.S.A., 79(6):1979-83 (1982).Applicant
• International Preliminary Report on Patentability with Written Opinion for App. Ser. No. PCT/JP2008/050842, dated Jul. 28, 2009, 6 pages.Applicant
• Fujiwara et al., “Control of tumor immunity by B cells and Th2 cytokines,” Annual Review Men'eki 1999:257-269 (1999) (with English translation).Applicant
• Kan et al., “The effect of anti-cancer agents on CD4+FoxP3+regulatory T Cell,” Dai 68 Kai Annual Meeting of the Japan Center Association, p. 286, P-0539 (2009).Applicant
• Narita et al., “Gemcitabine selectively depletes CD11b+ GR-1+ immature myeloid cells in tumor-bearing mice and enhances anti-tumor immune response,” Society for Fundamental Cancer Immunology Sokai Shoroku, 10:49 (2006) (with English translation).Applicant
• Yamamoto et al., “Regulatory Mechanisms for Production of IFN-γ and TNF by Antitumor T Cells or Macrophages in the Tumor-Bearing State,” Journal of Immunology, 154(5):2281-2290, The American Association of Immunologists, United States (1995).Applicant
• International Search Report for App. Ser. No. PCT/JP2011/062209, mailed on Jul. 12, 2011, 3 pages.Applicant
• Ceyhan et al., “Neural invasion in pancreatic cancer: a mutual tropism between neurons and cancer cells,” Biochem. Biophys. Res. Commun., 374:442-447 (2008).Applicant
• Maeda et al., “Essential Roles of IKKbeta / NF-κB Activation for Development of Liver Metastasis in Mice,” Gastroenterol, 130:P-1-P-350, Supplement 2, AASLD Abstracts, p. A-750, abstract No. 107, Elsevier Inc. (2006).Applicant
• Maeda et al., “Role of IKKbeta / NF-κB Activation for Development of Liver Metastasis,” Supplement: The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Hepatol., 46:Issue Supplement S1, AASLD Abstracts, p. 518A, abstract No. 630, American Association for the Study of Liver Diseases (2007).Applicant